Medicines Regulation and the TGA — (1999) Role of the Sponsor (28 March — 2013) TGA Labelling and Packaging Regulatory Framework (28 October — 2014) The Therapeutic Goods Risk Management Approach to the — Administration’s Regulation of Therapeutic Goods (2011) 6 Commonwealth Department of Health—Therapeutic Goods Administration (Advisory Committee on Medicines Scheduling), Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health, March 2015 (19 March 2015) Commonwealth Department of Infrastructure and Regional Development, Australian Government, Fact Sheet: Answers to Your Questions from the Information Sessions (May 2015) Cougle, J R et al, Stress Disorder and Cannabis Use in a Nationally ‘Posttraumatic Representative Sample’ (2011) 25 Psychologically Addictive Behaviors 554 Council of Australian Therapeutics Advisory Groups, Rethinking Medicines in Public Hospitals: Guiding Principles for the Quality Use of Off-Label Medicines (November 2013) Cridge, Belinda J and Rhonda J of the Potential Use of Rosengren, ‘Critical Appraisal Cannabinoids in Cancer (2013) 5 Cancer Management and Research 301 Management’ Curtis, Adrienne, Carl E Clarke and Hugh E Rickards, for ‘Cannabinoids Tourette’s (2009) 4 Cochrane Database of Systematic Reviews Syndrome’ Decorte, Tom, Social Clubs in Belgium: Organisational Strengths and ‘Cannabis Weaknesses, and Threats to the (2014) 26 International Journal of Drug Policy Model’ 122 Decorte, Tom et al (eds) World Wide Weed: Global Trends in Cannabis Cultivation and Its Control (Ashgate, 2011) and Mohini Ranganathan, Marijuana: Is the Before the Deepak Cyril D’Souza ‘Medical (2015) 313 Journal of the American Medical Association 2431 Horse?’ Degenhardt, Louisa and Wayne D Hall, Adverse Effects of Cannabinoids: ‘The Implications for Use of Medical 178(13) Canadian Medical Association Journal Marijuana’ (2008) 1685 Delourme, J et al, of Inhalation of Adulterated ‘Respiratory Consequences Cannabis’ (2009) 26 La Revue des Maladies Respiratoires 552 (French) Delsys Research Group, Final Report: Cost-Benefit Analysis of Regulatory Changes for Access to Marihuana for Medical Purposes (2012)
— Medicines Regulation and the TGA (1999) — Role of the Sponsor (28 March 2013) — TGA Labelling and Packaging Regulatory Framework (28 October 2014) — The Therapeutic Goods Administration’s Risk Management Approach to the Regulation of Therapeutic Goods (2011) 6 Commonwealth Department of Health—Therapeutic Goods Administration (Advisory Committee on Medicines Scheduling), Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health, March 2015 (19 March 2015) Commonwealth Department of Infrastructure and Regional Development, Australian Government, Fact Sheet: Answers to Your Questions from the Information Sessions (May 2015) Cougle, J R et al, ‘Posttraumatic Stress Disorder and Cannabis Use in a Nationally Representative Sample’ (2011) 25 Psychologically Addictive Behaviors 554 Council of Australian Therapeutics Advisory Groups, Rethinking Medicines in Public Hospitals: Guiding Principles for the Quality Use of Off-Label Medicines (November 2013) Cridge, Belinda J and Rhonda J Rosengren, ‘Critical Appraisal of the Potential Use of Cannabinoids in Cancer Management’ (2013) 5 Cancer Management and Research 301 Curtis, Adrienne, Carl E Clarke and Hugh E Rickards, ‘Cannabinoids for Tourette’s Syndrome’ (2009) 4 Cochrane Database of Systematic Reviews Decorte, Tom, ‘Cannabis Social Clubs in Belgium: Organisational Strengths and Weaknesses, and Threats to the Model’ (2014) 26 International Journal of Drug Policy 122 Decorte, Tom et al (eds) World Wide Weed: Global Trends in Cannabis Cultivation and Its Control (Ashgate, 2011) Deepak Cyril D’Souza and Mohini Ranganathan, ‘Medical Marijuana: Is the Before the Horse?’ (2015) 313 Journal of the American Medical Association 2431 Degenhardt, Louisa and Wayne D Hall, ‘The Adverse Effects of Cannabinoids: Implications for Use of Medical Marijuana’ (2008) 178(13) Canadian Medical Association Journal 1685 Delourme, J et al, ‘Respiratory Consequences of Inhalation of Adulterated Cannabis’ (2009) 26 La Revue des Maladies Respiratoires 552 (French) Delsys Research Group, Final Report: Cost-Benefit Analysis of Regulatory Changes for Access to Marihuana for Medical Purposes (2012)
VLRC_Medicinal_Cannabis_Report_web.docx